FIELD: medicine; pharmaceutics.
SUBSTANCE: present invention relates to use of cortexolone 17α-valerate for preparing a pharmaceutical composition, which is used to treat tumour diseases, as well as a pharmaceutical composition. Tumour diseases are epithelial tumours selected from prostate carcinoma, breast carcinoma; pancreatic carcinoma and colon carcinoma.
EFFECT: use of a cortexolone derivative for treating various tumour diseases.
15 cl, 18 dwg, 9 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN TREATMENT OF TUMOURS | 2015 |
|
RU2712950C2 |
| 17ALPHA-BENZOATE OF CORTEXOLONE FOR USE IN TREATING TUMOURS | 2015 |
|
RU2712752C2 |
| COMPOSITIONS AND METHODS OF TREATING ANDROGEN-RECEPTOR-POSITIVE CANCER | 2020 |
|
RU2817802C2 |
| SUPPRESSION OF CANCER METASTASES | 2010 |
|
RU2571502C2 |
| METHOD OF PREVENTION AND/OR TREATMENT OF CANCEROUS DISEASES | 2006 |
|
RU2480201C2 |
| INHIBITORS OF CELL CYCLE CHECKPOINT KINASE 1 FOR AMPLIFICATION OF DNA-DAMAGING AGENTS | 2010 |
|
RU2567044C2 |
| COMBINED THERAPY WITH CLAUDINE 18.2 ANTIBODIES FOR CANCER TREATMENT | 2014 |
|
RU2699549C2 |
| ANTI-CANCER THERAPY, DIRECTED AGAINST CANCER STEM CELLS AND FORMS OF CANCER, RESISTANT TO TREATMENT BY MEDICATIONS | 2010 |
|
RU2568834C2 |
| COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
| TREATMENT OF CANCER BY PARVOVIRUS IN COMBINATION WITH BEVACIZUMAB | 2016 |
|
RU2679442C1 |
